Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2017 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the following investor conferences:
- The Robert W. Baird’s 2017 Global Healthcare Conference in New York on September 6, 2017 at 7:55 a.m. Eastern Time
- The Ladenburg Thalmann 2017 Healthcare Conference in New York on September 26, 2017 at 9:30 a.m. Eastern Time
- The Cantor Fitzgerald Global Healthcare Conference in New York on September 27, 2017 at 3:25 p.m. Eastern Time
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst has several ongoing development programs: BCX7353 and other second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Japan, Taiwan and Korea. Post-marketing commitment development activities for RAPIVAB are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910
